Pitavastatin ethyl ester
CAS: 167073-19-0
Ref. 3D-SGA07319
| 25mg | Discontinued | ||
| 50mg | Discontinued | ||
| 100mg | Discontinued | ||
| 250mg | Discontinued | ||
| 500mg | Discontinued |
Product Information
- 2H-1,3,2-oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-3-methyl-4-(propylthio)-, 2-oxide
- N,N-bis(2-chloroethyl)-3-methyl-4-(propylsulfanyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
Pitavastatin ethyl ester is a sodium salt of pitavastatin, an urea nitrogen-containing statin drug. Pitavastatin ethyl ester is a prodrug that is hydrolyzed to its active form in vivo. The synthesis of pitavastatin ethyl ester starts with the addition of 1 equivalent of ethyl bromoacetate to the carboxylic acid group of pitavastatin, followed by the addition of 2 equivalents of potassium carbonate and 1 equivalent of sodium hydroxide. This reaction produces an incomplete ester because the carboxylic acid group remains unreacted. This can be remedied by adding one more equivalent each of ethyl bromoacetate and potassium carbonate.
Pitavastatin ethyl ester has been shown to have carcinogenic potential in vitro on human hepatocytes, but not in vivo on rats or mice. It has also been shown to reduce myocardial
